1. Scrip

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

 
• By Anju Ghangurde

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

All Eyes On Regulatory Traction For Biocon's Insulin Aspart • Source: Shutterstock

Things may not have played out to plan for Biocon, Ltd.’s partnered biosimilar rival to NovoLog (insulin aspart), but the Indian firm is hopeful that a US approval should be in place towards the end of 2022.

While a response to the US Food and Drug Administration (FDA) complete response letter for the Viatris Inc.-partnered biosimilar...

More from Business

More from Scrip